Advanced in Acute Myelomonocytic Leukemia

Dr. Naveen Pemmaraju

Houston, TX
Advanced
in Acute Myelomonocytic Leukemia
Specialties:Oncology | Hematology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Naveen Pemmaraju is an Oncologist and a Hematologist in Houston, Texas. Dr. Pemmaraju and is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 409 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 1 clinical trial in the study of Acute Myelomonocytic Leukemia.

Specialties
Oncology
Hematology
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

MD Anderson
2130 W Holcombe Blvd, Life Sciences Plaza, Houston, TX 77030
713-592-5433

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment Status: Terminated
Publish Date: July 22, 2024
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Other, Drug
Study Drug: LCL161 Smac Mimetic
Study Phase: Phase 2
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination With Azacytidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination With Azacytidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Azacitidine, PLX51107
Study Phase: Phase 1
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Enrollment Status: Withdrawn
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drugs: APG-1252, Ruxolitinib
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

408 Total Publications

BPDCN: state of the art.
BPDCN: state of the art.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 07, 2024
Similar Doctors
Expertise in
42
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology
Expertise in
42
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia and is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
34
conditions
Dr. Gautam M. Borthakur
Hematology | Oncology
Expertise in
34
conditions
Dr. Gautam M. Borthakur
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gautam Borthakur is a Hematologist and an Oncologist in Houston, Texas. Dr. Borthakur and is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Hagop M. Kantarjian
Expertise in
48
conditions
Dr. Hagop M. Kantarjian
Oncology | Hematology
Expertise in
48
conditions
Dr. Hagop M. Kantarjian
Oncology | Hematology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.6 mi)
713-792-6127
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist and a Hematologist in Houston, Texas. Dr. Kantarjian and is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile